Yong Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yong Yuan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Huahui Zeng
Academy of Chinese Medical Sciences , Henan University of Chinese Medicine , Zhengzhou , 450046 , China
1 shared publication - Junying Song
Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, China
1 shared publication - Kun Chen
Pharmacy College, Henan University of Chinese Medicine, Zhengzhou 450046, China
1 shared publication - Lan Zhang
Academy of Chinese Medicine Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China
1 shared publication - Min Yan
Academy of Chinese Medicine Sciences, Henan University of Chinese Medicine, Zhengzhou 450046, China
1 shared publication - Qikang Tian
Pharmacy College, Henan University of Chinese Medicine, Zhengzhou 450046, China
1 shared publication
Latest Publications
- Open Access
- 26 February 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (3) , 202
Novel Carboxylated Chitosan-Based Triptolide Conjugate for the Treatment of Rheumatoid Arthritis
A new platform for triptolide (TP) delivery was prepared by conjugating TP to a carboxylmethyl chitosan (CMCS). Compared with the natural TP, the TP-conjugate (TP-CMCS) containing TP of ~5 wt% exhibited excellent aqueous solubility (>5 mg/mL). Results of in vitro experiments showed that TP-CMCS could relieve TP-induced inhibition on RAW264.7 cells and apoptosis, respectively. Compared with the TP group, TP-CMCS could effectively alleviate the toxicity injury of TP and decreased the mortality rate of the mice (p < 0.05). TP-CMCS did not cause much damage to the liver (AST and ALT) and kidney (BUN and CRE) (p < 0.05). After administration, the levels of IL-6, IL-1β, and TNF-α decreased, and the arthritis detumescence percentages increased significantly, and the bony erosion degree was distinctly decreased in the TP-CMCS groups and TP group. Our results suggested that TP-CMCS was a useful carrier for the treatment of RA, which enhanced aqueous solubility of free TP and reduced drug toxicity in vitro and in vivo.
- 26 February 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (3) , 202
Open AccessNovel Carboxylated Chitosan-Based Triptolide Conjugate for the Treatment of Rheumatoid Arthritis
A new platform for triptolide (TP) delivery was prepared by conjugating TP to a carboxylmethyl chitosan (CMCS). Compared with the natural TP, the TP-conjugate (TP-CMCS) containing TP of ~5 wt% exhibited excellent aqueous solubility (>5 mg/mL). Results of in vitro experiments showed that TP-CMCS could relieve TP-induced inhibition on RAW264.7 cells and apoptosis, respectively. Compared with the TP group, TP-CMCS could effectively alleviate the toxicity injury of TP and decreased the mortality rate of the mice (p < 0.05). TP-CMCS did not cause much damage to the liver (AST and ALT) and kidney (BUN and CRE) (p < 0.05). After administration, the levels of IL-6, IL-1β, and TNF-α decreased, and the arthritis detumescence percentages increased significantly, and the bony erosion degree was distinctly decreased in the TP-CMCS groups and TP group. Our results suggested that TP-CMCS was a useful carrier for the treatment of RA, which enhanced aqueous solubility of free TP and reduced drug toxicity in vitro and in vivo.